Ginkgo Bioworks Holdings, Inc.
Datakwaliteit: 100%
€ 6,38
▼
€ 0,51
(-7,34%)
Marktkapitalisatie: 394,77 M
Prijs
€ 6,38
Marktkapitalisatie
394,77 M
Dagbereik
€ 6,24 — € 6,73
52-Weeksbereik
€ 5,37 — € 17,58
Volume
682.741
Openen € 6,67
50D / 200D Gem.
€ 7,91
19,43% below
50D / 200D Gem.
€ 10,29
38,03% below
Quick Summary
Belangrijkste Punten
Revenue declined -14,19% annually over 5 years
Negative free cash flow of -178,72 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 10,87%
Capital efficient — spends only 4,50% of revenue on capex
Groei
Revenue Growth (5Y)
-14,19%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)-25,06%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-53,34%
Boven sectorgemiddelde (-53,41%)
ROIC-22,56%
Net Margin-183,81%
Op. Margin-185,29%
Veiligheid
Debt / Equity
N/A
Current Ratio4,39
Interest CoverageN/A
Waardering
PE (TTM)
-1,26
Boven sectorgemiddelde (-1,48)
P/B Ratio0,71
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -1,3 | -1,5 |
| P/B | 0,7 | 1,6 |
| ROE % | -53,3 | -53,4 |
| Net Margin % | -183,8 | -41,5 |
| Rev Growth 5Y % | -14,2 | 1,8 |
| D/E | — | 0,3 |
ETFs Holding This Stock
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -25,06% | Revenue Growth (3Y) | -17,74% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -14,19% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 170,16 M | Net Income (TTM) | -312,76 M |
| ROE | -53,34% | ROA | -25,85% |
| Gross Margin | N/A | Operating Margin | -185,29% |
| Net Margin | -183,81% | Free Cash Flow (TTM) | -178,72 M |
| ROIC | -22,56% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 4,39 |
| Interest Coverage | N/A | Asset Turnover | 0,14 |
| Working Capital | 390,80 M | Tangible Book Value | 498,26 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1,26 | Forward P/E | N/A |
| P/B Ratio | 0,71 | P/S Ratio | 2,32 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -45,27% | ||
| Market Cap | 394,77 M | Enterprise Value | 283,70 M |
| Per Share | |||
| EPS (Diluted TTM) | -5,64 | Revenue / Share | 2,75 |
| FCF / Share | -2,89 | OCF / Share | -2,76 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 4,50% | FCF Conversion | 57,14% |
| SBC-Adj. FCF | -253,10 M | Growth Momentum | -10,87 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 170,16 M | 227,04 M | 251,46 M | 477,71 M | 313,84 M |
| Net Income | -312,76 M | -547,03 M | -892,87 M | -2,10 B | -1,83 B |
| EPS (Diluted) | -5,64 | -10,54 | -0,46 | -1,25 | -1,39 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -315,28 M | -559,76 M | -864,41 M | -2,21 B | -1,83 B |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 243,77 M | 424,06 M | 580,62 M | 1,05 B | 1,15 B |
| SG&A Expenses | — | — | — | — | — |
| D&A | 58,99 M | 63,02 M | 70,51 M | 42,55 M | 29,08 M |
| Interest Expense | 0,0 | 94.000,0 | 93.000,0 | 106.000,0 | 2,37 M |
| Income Tax | -837.000,0 | -479.000,0 | -71.000,0 | -15,03 M | -1,48 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1,12 B | 1,38 B | 1,67 B | 2,54 B | 2,07 B |
| Total Liabilities | 611,11 M | 661,39 M | 568,19 M | 803,04 M | 503,61 M |
| Shareholders' Equity | 508,59 M | 716,06 M | 1,10 B | 1,74 B | 1,51 B |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 167,20 M | 561,57 M | 944,07 M | 1,32 B | 1,55 B |
| Current Assets | 471,84 M | 602,74 M | 1,00 B | 1,45 B | 1,72 B |
| Current Liabilities | 95,97 M | 107,27 M | 163,86 M | 172,96 M | 134,76 M |
{"event":"ticker_viewed","properties":{"ticker":"DNA","listing_kind":"stock","pathname":"/stocks/dna","exchange":"NYSE","country":"US"}}

